Muscular Dystrophy Canada fund nine new projects through 2023 grant program
NMD4C Investigators involved in many of these exciting clinical and translational research projects
On Thursday March 30th, Muscular Dystrophy Canada (MDC) announced the results of their 2023 Neuromuscular Clinical and Translational Research Grant Program. A dedicated Canadian source of funding for neuromuscular research, this annual funding competition invests in clinical and translational research projects related to the diagnosis, treatment, or clinical care of neuromuscular disorders. These research grants help fill current gaps in the funding landscape.
This year we are pleased to celebrate the many NMD4C investigators and members who are leading and supporting MDC-funded projects! You can find the full list of funded projects on MDC’s website.
2023 Clinical Research Projects
Establishing the Top Ten Research Priorities for Respiratory Care of Childhood Neuromuscular Disorders ($50,000)
NMD4C investigators and collaborators as project co-investigators and collaborators
Dietary Protein Requirements in Adults with Muscular Dystrophy ($100,000)
Project Lead
Dr Tyler Churchward-Venne
McGill University
NMD4C member as project co-investigator
Dr Mark Tarnopolsky
Muscle MRI in neuromuscular disorders. The era of Artificial Intelligence ($100,000)
NMD4C investigator as project collaborator
B-FIT! Taking exercise away from the hospital into the home environment in people with Oculopharyngeal muscular dystrophy ($100,000)
Project Lead
Dr Eric Voorn
University of Amsterdam
NMD4C investigators and members as project co-investigators and collaborators
Reimagining Rehabilitation for SMA: Patient and Family Perspectives ($83,166)
Project Lead
Dr Jill Glennis Zwicker
University of British Columbia
NMD4C investigators and members as project co-investigators and collaborators
Translational Research Grants
Therapy development for centronuclear myopathy caused by DNM2 gene changes ($100,000)
How genealogies (family histories) can help us understand myotonic dystrophy type 1 ($99,600)
Project Lead
Dr Simon Girard
Université du Québec à Chicoutimi
NMD4C investigators as project co-investigators
Evaluating the impact of stop variants on MLIP’s (Muscular LMNA-Interacting Protein) function in muscle ($100, 000)
Pre-clinical testing of novel pharmacological inhibitors of toxic DMPK mRNA in models of myotonic dystrophy type 1 ($100 000)
Project Lead
Dr Pascal Chartrand
University of Montreal
Read next...
Important Deadlines for Ottawa NMD 2023
The Ottawa International Conference on Neuromuscular Disease and Biology (Ottawa NMD 2023) deadline for discounted early-bird registration and abstract submission is June 30th!
European Neuromuscular Centre Mid-Career Mentoring Programme Now Open
The European Neuromuscular Centre (ENMC) Mid-Career Mentoring Programme is now open for the third round of mentee candidates!
$6 million Brain Canada grant awarded to McGill to develop virtual integrated patient platform
NMD4C are pleased to share that The Neuro has received a $6 million grant from Brain Canada to fund a new Open Science patient registry to share data with researchers around the world and let patients see how their data is used to develop new treatments for neurological disorders.
CIHR Report: What we heard on the future of clinical trials
The Canadian Institute of Health Research (CIHR) have recently released an article outlining the results of their building the future of clinical trials consultation in a What We Heard report.
New Publication from NMD4C Investigators: Variability in Newborn Screening Across Canada: Spinal Muscular Atrophy and Beyond
A new study ‘Variability in Newborn Screening Across Canada: Spinal Muscular Atrophy and Beyond’ examines the differences between provincial newborn screening (NBS) programs and the variability of Spinal muscular atrophy (SMA) screening inclusion within these.
National strategy for drugs for rare disease update
Health Canada announced a new funding plan to support the first-ever national strategy for drugs for rare disease, with an investment of $1.5 billion over three years. This national strategy will increase access to, and affordability of, effective drugs for rare diseases to improve the health of patients across Canada.